Support our Foundation of Myology project
1722 news items
ERN EURO-NMD webinar, 5 March: Prof. Ammar Al-Chalabi (UK)
On 05/03/2026
Autonomic and non-motor symptoms in ALS Thursday 05 March 2026 – 16:00-17:00 Paris time Prof. Ammar Al-Chalabi (King’s College London, UK) > + infos Organized by…
BIND: a tool for better identifying and assessing central nervous system involvement in DMD
On 05/03/2026
An international consortium of researchers has developed and validated a new tool for studying disorders related to central nervous system damage (learning disorders, etc.) in…
Limited efficacy of using AAV-U7 to deliver antisense oligonucleotides to the brains of DMD mouse models
On 05/03/2026
Researchers at the University of Versailles-Saint-Quentin tested antisense oligonucleotides (ASOs) targeting exon 51 skipping of the DMD gene in mdx52 mice, models of Duchenne muscular…
German-speaking real-world data on the use of innovative therapies in SMA
On 04/03/2026
Researchers consulted the SMArtCARE registry, which focuses on SMA in Germany, Austria and Switzerland, in the context of innovative therapies available since 2017: data from…
Genotyping of a large cohort of neuromuscular patients in Iran
On 04/03/2026
Iranian clinicians and biologists report the results of genotyping 2,009 individuals with various neuromuscular diseases (including spastic paraplegia and hereditary ataxia): patients were recruited from…
A case of Lambert-Eaton syndrome successfully treated with efgartigimod
On 03/03/2026
Chinese clinicians report the case of a 73-year-old patient diagnosed with Lambert-Eaton myasthenic syndrome (LEMS) who underwent treatment with a latest-generation immunosuppressant: the patient met…
Organoids to understand the limited effectiveness of gene therapy in DMD
On 02/03/2026
Researchers at the Institute of Myology* and Genethon have developed muscle organoids, called ‘MYOrganoids’, that reproduce Duchenne muscular dystrophy (DMD) in order to study gene…
Givinosat (Duvysat®) receives unfavourable opinion on reimbursement from the HAS in DMD
On 25/02/2026
Givinostat (Duvyzat®) has had conditional European marketing authorisation since June 2025 for boys aged 6 years and older with Duchenne muscular dystrophy (DMD) who are…
ERN EURO-NMD webinar, 26 Feb.: Prof. Jim Bonham (UK)
On 20/02/2026
Genetics Month episode 4: Newborn Screening and Impact on Rare Diseases Thursday 26 February 2026 – 16:00-17:00 Paris time Prof. Jim Bonham (President of the…
Klaudia Kuranda joins the Institute of Myology and Genethon to create a center of expertise dedicated to immunology
On 19/02/2026
An internationally recognized expert in the field of immunology and the development of gene therapies, Klaudia Kuranda is joining the AFM-Téléthon laboratories to establish and lead a new Immunology Center that will bring together…
SYNAPSE-CMT trial: NMD Pharma announces preliminary results
On 18/02/2026
The SYNAPSE-CMT Phase IIa clinical trial evaluated NMD670 (ignaseclant) administered orally twice daily, compared to placebo, in 81 adults with Charcot-Marie-Tooth disease (CMT1 and CMT2)…
First Network-Wide Event ENTRY-DM: a European launch in Paris to train a new generation of researchers
On 16/02/2026
The ENTRY-DM doctoral network (Interdisciplinary doctoral training on oligonucleotide-based therapies for myotonic dystrophy) officially launched in March 2025, and the 14 international doctoral students recruited…
Lamotrigine appears to be effective over two years in channelopathies
On 16/02/2026
Used as an alternative to mexiletine in the treatment of non-dystrophic myotonia, lamotrigine shows lasting efficacy in a new British study: it involved 37 patients…
ERN EURO-NMD webinar, 19 Feb.: Dr. Marcella Ner (Italy)
On 13/02/2026
Genetics Month episode 3: Genetics of Amyotrophic Lateral Sclerosis and Impact on New Therapies Thursday 19 February 2026 – 16:00-17:00 Paris time Dr. Marcella Neri…
Intrathecal gene therapy Itvisma effective in two Phase III trials in SMA
On 13/02/2026
In SMN1-related proximal spinal muscular atrophy (SMA), the intravenous treatment Zolgensma is indicated for infants and young children weighing less than 21 kg with type…
Full speed ahead to the 4th Muscle Week and the 2026 Muscle Conference!
On 12/02/2026
The Winter Olympic Games offer a timely reminder of a fundamental truth: muscle is not only responsible for athletic prowess and sporting performance, it is, above all, a major public health issue. By interacting with many organs,…
The Institute acquires a new, latest-generation multimodal confocal microscope
On 12/02/2026
Bruno Cadot, researcher at the Center of Research in Myology and head of the MyoImage technology platform, oversaw the acquisition of a latest-generation Nikon AXR-NSPARC confocal…
ERN EURO-NMD webinar, 12 Feb.: Dr. Fernanda Fortunato (Italy)
On 09/02/2026
Genetics Month episode 2: CPMS Use and Value for Genetic Case Discussions Thursday, 12 February 2026 – 16:00-17:00 Paris time Dr. Fernanda Fortunato (University Hospital…
Effects of exoskeletons on mobility and motor function in MND patients
On 05/02/2026
Neuromuscular diseases (NMDs) cause progressive muscle weakness that significantly impairs patients’ functional abilities and quality of life. Romain Feigean, researchers in Neuromuscular Physiology and Evaluation…
A new FDX2 mutation identified in a form of mitochondrial myopathy
On 05/02/2026
An Italian team studied the case of a 9-year-old patient with a mitochondrial myopathy called MEOAL (Mitochondrial Episodic Myopathy with or without Optic Atrophy and…
